| Matthew T Moyer, MD | |
|
500 University Dr, H088, Hershey, PA 17033-2360 | |
| (717) 531-4950 | |
| (717) 531-4870 |
| Full Name | Matthew T Moyer |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 22 Years |
| Location | 500 University Dr, Hershey, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417174749 | NPI | - | NPPES |
| 1021873040001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD425006 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Holy Spirit Hospital | Camp hill, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Milton S Hershey Medical Center Physicians Group | 3870405483 | 1400 |
News Archive
A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
As Western countries gear up for a second wave of the coronavirus disease (COVID-19) pandemic, a new study shows that this time around, the worst-hit in terms of case numbers is the young adult age group, between 18 and 29 years. This finding could be crucial in framing dynamic public health measures, which will contain and help limit rising cases.
A large study co-authored by Penn Medicine published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status.
› Verified 9 days ago
| Entity Name | Hershey Endoscopy Center Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1710985445 PECOS PAC ID: 4587560123 Enrollment ID: O20031212000283 |
News Archive
A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
As Western countries gear up for a second wave of the coronavirus disease (COVID-19) pandemic, a new study shows that this time around, the worst-hit in terms of case numbers is the young adult age group, between 18 and 29 years. This finding could be crucial in framing dynamic public health measures, which will contain and help limit rising cases.
A large study co-authored by Penn Medicine published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status.
› Verified 9 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
As Western countries gear up for a second wave of the coronavirus disease (COVID-19) pandemic, a new study shows that this time around, the worst-hit in terms of case numbers is the young adult age group, between 18 and 29 years. This finding could be crucial in framing dynamic public health measures, which will contain and help limit rising cases.
A large study co-authored by Penn Medicine published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew T Moyer, MD Po Box 858, Mc A410, Hershey, PA 17033-0858 Ph: (800) 243-1455 | Matthew T Moyer, MD 500 University Dr, H088, Hershey, PA 17033-2360 Ph: (717) 531-4950 |
News Archive
A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.
Duke University biologists have evolved a complex trait in the laboratory - using the pressure of selection to induce tobacco hornworms to evolve the dual trait of turning black or green depending on the temperature during their development.
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
As Western countries gear up for a second wave of the coronavirus disease (COVID-19) pandemic, a new study shows that this time around, the worst-hit in terms of case numbers is the young adult age group, between 18 and 29 years. This finding could be crucial in framing dynamic public health measures, which will contain and help limit rising cases.
A large study co-authored by Penn Medicine published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status.
› Verified 9 days ago
Nicole Swallow, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, H088, Hershey, PA 17033 Phone: 717-531-1692 | |
Karen Louise Krok, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 Fax: 717-531-0061 | |
James O Ballard, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-233-4082 | |
Poonam Na Bai, Gastroenterology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-6585 | |
Wilbert Hoffman Beachy Iv, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-7300 | |
Samer Nabil Muallem, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Dr. Robert David Aronoff, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 |